HEALTH TECHNOLOGY

Stryker Launches Q Guidance System with Spine Guidance Software

Stryker | September 28, 2022 | Read time : 03:00 min

Stryker Launches

Stryker one of the world’s leading medical technology companies, announced the launch of its Q Guidance System for spine applications. The System combines new optical tracking options provided by a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Spine Guidance Software to deliver more surgical planning and navigation capability than ever before. When used with the Q Guidance System, the Spine Guidance Software is intended as a planning and intraoperative guidance system to enable open or percutaneous computer-assisted surgery and is the first spine navigation software to receive FDA clearance for use with pediatric patients aged 13 and older.

The Q Guidance System offers cutting-edge tracking options with its 4th generation FP8000 camera, and Spine Guidance Software allows for advanced planning and computer-assisted execution. With the addition of the Q Guidance System, customers now have access to a robust solution that includes imaging, guidance, and instruments and is fully integrated and designed to meet complex customer needs. In the years to come, our goal is to use the versatility of this System to help advance our technologies across multiple specialties including cranial, spine, ENT, and orthopaedics.”

Robbie Robinson, President of the Spine division

Q Guidance offers surgeons numerous benefits, including

  • A proprietary camera: The Q Guidance System features a 4th generation FP8000 camera that offers unmatched speeds and the flexibility of multiple optical tracking methods, including full-spectrum active/passive hybrid optical tracking.1 It is the only guidance system with proprietary active technology and a non-invasive patient tracker, SpineMask.
  • Image processing: Spine Guidance Software features completely redesigned applications, semi-automatic and automatic processing features, gesture recognition, and broad compatibility with various types of image sets.
  • Spine Guidance Software: Spine Guidance Software is designed to help surgeons optimize their workflow, minimize their time in the OR and address complex clinical decisions and techniques intraoperatively. Its computational power is designed to support our spine product and software roadmap. It is our intention to develop and release new technologies within the Q ecosystem.

“In my experience, Spine Guidance Software truly simplifies preoperative planning, navigation and execution,” said Stephen George, M.D., Director of Spine Surgery, Nicklaus Children's Hospital. “From what I have seen, the Q Guidance System is a powerful platform that has provided reliability and performance in a solution that is conveniently scalable to a wide array of surgical procedures, ranging from a single level fusion to a multi-level deformity correction. When used with the Airo TruCT scanner, Spine Guidance Software is designed to minimize time spent intraoperatively planning, thanks to its auto segmentation capability, while also allowing us the benefit of being able to image the patient in the surgical position. Its intuitive and customizable software enables us to configure the System to fit our preferences.”

Stryker will be featuring the Q Guidance System and offering demonstrations at several upcoming meetings, including

  • Society for Minimally Invasive Spine Surgery (SMISS) 2022 Annual Forum in Las Vegas, Sept. 29–Oct. 1, 2022
  • Congress of Neurological Surgeons (CNS) 2022 Annual Meeting in San Francisco, Oct. 8–12, 2022
  • North American Spine Society (NASS) Annual Meeting in Chicago, Oct. 12–15, 2022

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, and Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 100 million patients annually. 

Spotlight

In the pursuit of Europe’s greatest health potential by the year 2020, to accelerate gains in health outcomes and reduce health inequalities the delivery of health services must continuously adapt and evolve according to changing demographics and the epidemiological landscape. Both this context and what changes it calls for are clear. For example, aging populations have given rise to increases in noncommunicable diseases (NCDs), multi-morbidities and chronicity.

Spotlight

In the pursuit of Europe’s greatest health potential by the year 2020, to accelerate gains in health outcomes and reduce health inequalities the delivery of health services must continuously adapt and evolve according to changing demographics and the epidemiological landscape. Both this context and what changes it calls for are clear. For example, aging populations have given rise to increases in noncommunicable diseases (NCDs), multi-morbidities and chronicity.

Related News

HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market. The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA. "This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States," Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation About the LAmbre™ Plus LAA Closure System LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world. About LifeTech Scientific Corporation Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Read More

HEALTH TECHNOLOGY

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

Perimeter Medical Imaging AI, Inc. | September 30, 2022

Perimeter Medical Imaging AI, Inc. announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. “This commercial placement of our Perimeter S-Series OCT system at a hospital in a major healthcare network marks a significant milestone for us as we gain traction validating our commercial model. Perimeter S-Series OCT aims to improve patient outcomes and lower healthcare costs, and we are excited that leading surgeons and hospitals are seeing the potential of our ground-breaking technology.” Jeremy Sobotta, Perimeter’s Chief Executive Officer About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Read More

HEALTH TECHNOLOGY

Redox and Intelligent Medical Objects Partnering to Augment Healthcare Data

Redox Inc. | October 18, 2022

Redox, the company setting the stage for composable healthcare, has partnered with Intelligent Medical Objects, a healthcare data enablement company to standardize clinical data from diverse systems into consistent, structured, clinically validated terminology including comprehensive mapping to major global coding systems. Now healthcare companies can spend more time building improved patient and clinician experiences by eliminating the lengthy and taxing process of combining multiple point solutions. This announcement comes directly after last week's launch of API Actions, a modular way for healthcare companies to build out their ideal workflows. This present partnership between IMO and Redox benefits any healthcare company that receives clinical problem or diagnosis data from multiple organizations. As a result, these are further able to enrich healthcare data using consistent terminology across all data standards, formats, and workflows with a single Redox API. "Redox is dedicated to making sure that healthcare data can empower builders to create new experiences for patients and providers. We want to be clear that composable healthcare is a practice of bringing together the best technologies to produce the best solutions, and we're glad to be doing so with IMO." Redox CEO Luke Bonney "Clinical patient data is a powerful resource in healthcare. IMO partnering with Redox will accelerate the ability for healthcare companies to leverage that data to create better outcomes for doctors and patients," said IMO CEO Ann Barnes. Redox will leverage IMO's technology to standardize healthcare data for its customers. Using IMO Precision Normalize will allow Redox to accelerate data normalization for its hospital and software vendor clients. This lets healthcare technology companies spend more time building powerful solutions by eliminating the lengthy and costly process of cleaning and standardizing messy clinical data. SNOMED® is a registered trademark of International Health Terminology Standards Development Organisation About Redox Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before. About IMO Intelligent Medical Objects is a healthcare data enablement company. From clinical documentation at the point of care to complex approaches to population health management, IMO ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem. For almost three decades, IMO's footprint in EHRs—across more than 4,500 US hospitals—powers our expert ability to capture and preserve clinical intent wherever and however data is used. Our primary clients span individual doctors and physician groups, hospitals and clinics, large integrated delivery networks, inpatient ORs and surgical centers, global electronic health record providers, health information exchanges, clinical data registries, payers, life sciences companies, and healthcare analytics vendors.

Read More